Figure 2
(a) Localization of phosphoMARCKS (pMARCKS) phosphorylated at Ser162 and Ser159/163 in PBMC of MCL and CLL patients from the validation group and healthy controls. Cells were fixed and fluorescently labeled for pMARCKS at Ser162 or Ser159/163. DAPI was used for nuclear staining. Scale bars represent 5 μm. (b) Fluorescence intensity of the anti-pMARCKS (Ser162) antibody and anti-pMARCKS (Ser159/163) antibody in the cytoplasm and nucleus determined by IF in PBMC of MCL and CLL patients from the validation group. (c) Fluorescence intensity of the anti-MARCKS antibody in the cytoplasm and nucleus (and its ratio) in MEC-1 cell line, and miR-155 clones determined by IF. Each dot represents one cell. Results of Student’s t-test and Tukey’s honest significant difference statistical test are displayed. *P⩽0.05, **P⩽0.01, ****P⩽0.0001. MM, monoallelic mutation; BM, biallelic mutation.
